MAPT and Alzheimer disease: Preclinical studies report that DHA supplementation or endogenous conversion of n-6 PUFA into n-3 PUFA in 3xTg-AD mice reduce the levels of phosphorylated tau (17, 93), but none investigated EPA specifically.